Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Science Advances"
DOI: 10.1126/sciadv.aav2437
Abstract: In vivo–based functional genomic screen identifies DDR2 as an important determinant of efficacy of anti–PD-1 immunotherapy. While a fraction of cancer patients treated with anti–PD-1 show durable therapeutic responses, most remain unresponsive, highlighting the need… read more here.
Keywords: anti immunotherapy; response anti; targeting ddr2; tumor ... See more keywords